Abstract:The NLRP3 inflammasome is a critical component of innate immunity, which defends internal and external threats. However, inappropriate activation of the NLRP3 inflammasome induces various human diseases. In this study, we discovered and synthesized a series of tetrahydroquinoline inhibitors of NLRP3 inflammasome. Among these analogues, compound 6 exhibited optimal NLRP3 inhibitory activity. In vitro studies indicated that compound 6 directly bound to the NACHT domain of NLRP3 but not to protein pyrin domain (PYD) or LRR domain, inhibited NLRP3 ATPase activity, and blocked ASC oligomerization, thereby inhibiting NLRP3 inflammasome assembly and activation. Compound 6 specifically inhibited the NLRP3 inflammasome activation, but had no effect on the activation of NLRC4 or AIM2 inflammasomes. Furthermore, in the dextran sulfate sodium (DSS)-induced colitis mouse model, compound 6 exhibited significant anti-inflammatory activity through inhibiting NLRP3 inflammasome in vivo. Therefore, our study provides a potent NLRP3 inflammasome inhibitor, which deserves further structural optimization as a novel therapeutic candidate for NLRP3-driven diseases.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01924?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01924</a>.1H NMR, 13C NMR, and HPLC spectra analysis of all synthetic compounds; amino acid sequences of NLRP3 PYD domain, NACHT domain, and LRR domain; pharmacophore generation; pharmacophore and docking screening; small molecules in training set and testing set; and the activity tests of selected ligands (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_001.pdf">PDF</a>)Molecular formula strings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_002.csv">CSV</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_003.pdf">PDF</a>)Recommended compound characterization checklist (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01924/suppl_file/jm0c01924_si_004.xls">XLS</a>)This article has not yet been cited by other publications.

A Rhodium(III) Complex As an Inhibitor of Neural Precursor Cell Expressed, Developmentally Down-Regulated 8-Activating Enzyme with in Vivo Activity Against Inflammatory Bowel Disease

3-(2-Oxo-2-phenylethylidene)-2,3,6,7-tetrahydro-1h-pyrazino[2,1-a]isoquinolin-4(11bh)-one (compound 1), a Novel Potent Nrf2/ARE Inducer, Protects Against DSS-induced Colitis Via Inhibiting NLRP3 Inflammasome.

Rhodium(I) Complexes Containing the N^N^N-Chelating Ligand: Synthesis, Structure, and Biological Activity

Structure-Antiplatelet Activity Relationships of Novel Ruthenium (II) Complexes: Investigation of Its Molecular Targets

Discovery and Optimization of 4-Oxo-2-thioxo-thiazolidinones As NOD-like Receptor (NLR) Family, Pyrin Domain-Containing Protein 3 (NLRP3) Inhibitors.

A Novel CDK8 Inhibitor with Poly-Substituted Pyridine Core: Discovery and Anti-Inflammatory Activity Evaluation in Vivo

Development of Novel Tetrahydroquinoline Inhibitors of NLRP3 Inflammasome for Potential Treatment of DSS-Induced Mouse Colitis

Identification of an Iridium(III)-Based Inhibitor of Tumor Necrosis Factor-α

Design, Synthesis and Evaluation of a Series of Non-Steroidal Anti-Inflammatory Drug Conjugates As Novel Neuroinflammatory Inhibitors

Crystallography-Guided Optimizations of the Keap1-Nrf2 Inhibitors on the Solvent Exposed Region: from Symmetric to Asymmetric Naphthalenesulfonamides.

Development of Potent NEDD8-Activating Enzyme Inhibitors Bearing a Pyrimidotriazole Scaffold.

Design, Synthesis, and Bioevaluation of Novel NLRP3 Inhibitor with IBD Immunotherapy from the Virtual Screen

Discovery of 4-((E)-3,5-dimethoxy-2-((E)-2-nitrovinyl)styryl)aniline derivatives as potent and orally active NLRP3 inflammasome inhibitors for colitis

Design, synthesis and biological evaluation of novel diphenylamine analogues as NLRP3 inflammasome inhibitors

Antiangiogenic Ruthenium(ii) Benzimidazole Complexes, Structure-Based Activation of Distinct Signaling Pathways

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Structure-Activity and Structure-Property Relationship and Exploratory in Vivo Evaluation of the Nanomolar Keap1-Nrf2 Protein-Protein Interaction Inhibitor

A multi-target caffeine derived rhodium(i) N-heterocyclic carbene complex: evaluation of the mechanism of action.

A bioactive ligand-conjugated iridium(III) metal-based complex as a Keap1–Nrf2 protein-protein interaction inhibitor against acetaminophen-induced acute liver injury

Discovery of Benzothiazole Derivatives As Novel Non-Sulfamide NEDD8 Activating Enzyme Inhibitors by Target-Based Virtual Screening.

Rhodium(III) Complex Noncanonically Potentiates Antitumor Immune Responses by Inhibiting Wnt/β-Catenin Signaling